Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Express Scripts
Chubb
Cantor Fitzgerald
AstraZeneca
Mallinckrodt
Cipla
QuintilesIMS
Chinese Patent Office
US Department of Justice

Generated: October 22, 2017

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020981

« Back to Dashboard
NDA 020981 describes HYCAMTIN, which is a drug marketed by Novartis Pharms Corp and is included in two NDAs. It is available from two suppliers. There is one patent protecting this drug. Additional details are available on the HYCAMTIN profile page.

The generic ingredient in HYCAMTIN is topotecan hydrochloride. There are ten drug master file entries for this compound. Fourteen suppliers are listed for this compound. Additional details are available on the topotecan hydrochloride profile page.

Summary for NDA: 020981

Tradename:
1
Applicant:
1
Ingredient:
1
Patents:1
Formulation / Manufacturing:see details

Pharmacology for NDA: 020981

Mechanism of ActionTopoisomerase Inhibitors

Suppliers and Packaging for NDA: 020981

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL 020981 NDA GlaxoSmithKline LLC 0007-4205 0007-4205-11 10 CAPSULE in 1 BOTTLE (0007-4205-11)
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL 020981 NDA GlaxoSmithKline LLC 0007-4207 0007-4207-11 10 CAPSULE in 1 BOTTLE (0007-4207-11)

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 0.25MG BASE
Approval Date:Oct 11, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 10, 2024Product Flag?YSubstance Flag?Delist Request?

Summary for product number 002

Active Rx/OTC/Discontinued:RXDosage:CAPSULE;ORALStrengthEQ 1MG BASE
Approval Date:Oct 11, 2007TE:RLD:Yes
Patent:► SubscribePatent Expiration:Dec 10, 2024Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 020981

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-001Oct 11, 2007► Subscribe► Subscribe
Novartis Pharms Corp
HYCAMTIN
topotecan hydrochloride
CAPSULE;ORAL020981-002Oct 11, 2007► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

Accenture
Federal Trade Commission
Citi
Farmers Insurance
Cipla
Fish and Richardson
US Department of Justice
Colorcon
AstraZeneca
Harvard Business School

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot